CA2989144A1 - Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways - Google Patents

Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways Download PDF

Info

Publication number
CA2989144A1
CA2989144A1 CA2989144A CA2989144A CA2989144A1 CA 2989144 A1 CA2989144 A1 CA 2989144A1 CA 2989144 A CA2989144 A CA 2989144A CA 2989144 A CA2989144 A CA 2989144A CA 2989144 A1 CA2989144 A1 CA 2989144A1
Authority
CA
Canada
Prior art keywords
antibody
cxcr4
antigen
cancer
binds specifically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2989144A
Other languages
English (en)
French (fr)
Inventor
Josephine M. Cardarelli
Wendy L. CLEMENS
Glenn S. KROOG
Daniel E. Lopes De Menezes
Chin Pan
Paul D. Ponath
Jean Viallet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2989144A1 publication Critical patent/CA2989144A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2989144A 2015-06-12 2016-06-13 Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways Abandoned CA2989144A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174931P 2015-06-12 2015-06-12
US62/174,931 2015-06-12
PCT/US2016/037207 WO2016201425A1 (en) 2015-06-12 2016-06-13 Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

Publications (1)

Publication Number Publication Date
CA2989144A1 true CA2989144A1 (en) 2016-12-15

Family

ID=56194616

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989144A Abandoned CA2989144A1 (en) 2015-06-12 2016-06-13 Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

Country Status (9)

Country Link
US (1) US20180179282A1 (enExample)
EP (1) EP3307778A1 (enExample)
JP (1) JP2018516969A (enExample)
CN (1) CN108026173A (enExample)
BR (1) BR112017026189A2 (enExample)
CA (1) CA2989144A1 (enExample)
EA (1) EA201792522A1 (enExample)
MX (1) MX2017015811A (enExample)
WO (1) WO2016201425A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) * 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CN108883132A (zh) * 2016-01-22 2018-11-23 X4 制药有限公司 用于治疗癌症的方法
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
EP3548070A4 (en) * 2016-11-29 2020-07-22 Health Research, Inc. METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPY
EP3600395A4 (en) 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
CN113150068B (zh) * 2017-09-20 2023-04-04 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
JP2021502071A (ja) * 2017-11-07 2021-01-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんバイオマーカーおよびその使用方法
ES2973728T3 (es) * 2018-03-13 2024-06-24 Fundacion Para La Investigacion Biomedica Del Hospital Univ La Paz Anticuerpo anti-CXCR4 combinado con linfocitos citolíticos naturales activados y expandidos para inmunoterapia contra el cáncer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP7542529B2 (ja) * 2018-10-17 2024-08-30 バイオラインアールエックス・リミテッド 転移性膵臓腺癌の処置
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
EP3908664A4 (en) * 2019-01-07 2023-01-25 Thomas Jefferson University MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES
KR20210141621A (ko) * 2019-03-22 2021-11-23 스미토모 다이니폰 파마 온콜로지, 인크. Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
WO2022094299A2 (en) * 2020-10-30 2022-05-05 Janux Therapeutics, Inc. Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
US11958906B2 (en) 2022-04-13 2024-04-16 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2023201299A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
CN119451993A (zh) * 2022-05-04 2025-02-14 佳努克斯治疗公司 用于靶向cd28和pd-l1的肿瘤激活多特异性抗体及其使用方法
CN115487146B (zh) * 2022-10-28 2023-07-18 宁夏医科大学 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用
JP2025540021A (ja) * 2022-12-07 2025-12-11 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド 抗ｃｄ２４抗体及びｐｄ－１－ｐｄ－ｌ１経路遮断抗体を使用した癌に対する併用療法
CN115960269B (zh) * 2023-01-30 2026-04-03 上海甲贝医药科技有限公司 一种重组长效人cxcr4&pd-1双靶点抗体融合蛋白及其制备方法
CN120813375A (zh) * 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
CN102027015A (zh) 2008-05-14 2011-04-20 伊莱利利公司 抗cxcr4抗体
JP2012500855A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
EP2734234A4 (en) 2011-07-20 2015-01-28 Medimmune Ltd ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF
CN104039320B (zh) 2011-11-09 2019-10-15 百时美施贵宝公司 血液恶性肿瘤用抗-cxcr4抗体的治疗
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
EP3508215A3 (en) 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CA2919790C (en) 2013-08-02 2018-06-19 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
CA2920377A1 (en) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
CN108026173A (zh) 2018-05-11
JP2018516969A (ja) 2018-06-28
BR112017026189A2 (pt) 2018-08-14
MX2017015811A (es) 2018-04-10
WO2016201425A1 (en) 2016-12-15
US20180179282A1 (en) 2018-06-28
EA201792522A1 (ru) 2018-05-31
WO2016201425A9 (en) 2017-01-19
EP3307778A1 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
US20180179282A1 (en) Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
RU2766890C2 (ru) Комбинированные способы лечения антагонистами pd-l1
US10023649B2 (en) Method of treating cancer with a combination of an anti-CCR4 antibody and a 4-1BB agonist
CN106573977B (zh) 针对ceacam1的人源化抗体
JP2024020202A (ja) リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用
CN111699005A (zh) 使用抗cd47抗体和抗cd20抗体的抗癌方案
CN104470949A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
US20210054063A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
CA3224890A1 (en) Lag-3 antagonist therapy for hematological cancer
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
HK1248530B (en) Pd-l1 antagonist combination treatments

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301